Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10017804 | 0.88 | — | — | |
| SCHEMBL10447692 | 0.87 | TSHR (0.33) | ALDH1A1 | |
| SCHEMBL1561949 | 0.87 | TSHR (0.33) | ALDH1A1 | |
| SCHEMBL23905705 | 0.82 | — | — | |
| SCHEMBL18961181 | 0.82 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL938000 | 0.82 | LMNA (0.46) | — | |
| SCHEMBL15096043 | 0.80 | MEN1 (0.38) | ALDH1A1 | |
| SCHEMBL21914175 | 0.80 | MEN1 (0.33) | ALDH1A1 | |
| SCHEMBL9192589 | 0.79 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL1276341 | 0.79 | TSHR (0.40) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209223-A1 | CATIONIC UV-LED RADIATION CURABLE PROTECTIVE VARNISHES FOR SECURITY DOCUMENTS | SICPA HOLDING SA (CH) | 2024-06-27 | — | — | US | disclosed |
| US-20230357776-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11732265-B2 | Compositions and methods for modulating complement factor B expression | IONIS PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230151365-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-9714421-B2 | Compositions and methods | IONIS PHARMACEUTICALS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20170183661-A1 | COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170166899-A1 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170159055-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20160354476-A1 | TARGETED THERAPEUTIC NUCLEOSIDES AND THEIR USE | IONIS PHARMACEUTICALS, INC. (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160194349-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2016-07-07 | — | — | US | disclosed |
| US-20150176007-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150126719-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126718-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126720-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20140343123-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-7368516-B2 | Catalyst for trimerization of ethylene and process for trimerizing ethylene using the catalyst | TOSOH CORPORATION (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20050187419-A1 | Catalyst for trimerization of ethylene and process for trimerizing ethylene using the catalyst | TOSOH CORPORATION (JP) | 2005-08-25 | — | — | US | disclosed |
| US-6900152-B2 | Catalyst for trimerization of ethylene and process for trimerizing ethylene using the catalyst | TOSOH CORPORATION (JP) | 2005-05-31 | — | — | US | disclosed |
| US-20020035029-A1 | Catalyst for trimerization of ethylene and process for trimerizing ethylene using the catalyst | TOSOH CORPORATION (JP) | 2002-03-21 | — | — | US | disclosed |
| US-6337297-B1 | CHROMIUM CATALYST FOR TRIMERIZATION OF ETHYLENE WITH MULTIDENTATE LIGAND OR HALOGEN, CARBOXY GROUP | TOSOH CORPORATION (JP) | 2002-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354476-A1 | TARGETED THERAPEUTIC NUCLEOSIDES AND THEIR USE | FUT6, GALNT6, FUT5 | ALDH1A1 1445/4885 |
| US-20050187419-A1 | Catalyst for trimerization of ethylene and process for trimerizing ethylene using the catalyst | ACMSD, TAF9, ETV6 | ALDH1A1 2843/4885 |
| US-20230151365-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | TTR, GALNT1, GALNT3 | ALDH1A1 1286/4885 |
| US-20160194349-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | TEK, PLIN3, FABP3 | ALDH1A1 2808/4885 |
| US-20150176007-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | HAVCR2, HCCS, HDGF | ALDH1A1 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.